Form 4: BioXcel Director Miller Granted 17,000 Stock Options

BioXcel Therapeutics, Inc. Director Michael Patrick Miller was granted 17,000 stock options with an exercise price of $2.01.

Summary

• Michael Patrick Miller, a Director of BioXcel Therapeutics, Inc. (BTAI), was granted 17,000 stock options.
• The options have an exercise price of $2.01 per share.
• The grant date for these options was January 9, 2026.
• The options will vest on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, subject to continued service as a non-employee director.
• The options expire on January 9, 2036.
• Following this transaction, Mr. Miller beneficially owns 17,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a standard compensation practice, aligning director interests with shareholders, which is generally viewed favorably. It does not, however, provide new information on operational performance or financial health.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The exercise price of $2.01 provides a clear benchmark for future stock performance required for the options to be in-the-money.

Risks

• The value of the stock options is entirely dependent on the future performance of BioXcel Therapeutics, Inc.'s common stock. If the stock price does not rise above the exercise price of $2.01, the options may expire worthless.
• The vesting schedule requires Michael Patrick Miller to continue in service as a non-employee director through the vesting date, posing a risk if his service is terminated prior to vesting.

Future Outlook

The grant of stock options to a director suggests an expectation of future value creation for BioXcel Therapeutics, Inc., as the options only become profitable if the stock price appreciates above the exercise price.

Industry Context

Stock option grants are a standard component of executive and director compensation packages across various industries, particularly in growth-oriented sectors like biotechnology and pharmaceuticals. This practice aims to align the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice among publicly traded companies, especially within the biotechnology sector, to attract and retain qualified board members and incentivize performance.
• The specific number of options (17,000) and the exercise price ($2.01) would typically be evaluated against similar grants at peer companies within the small-to-mid cap biotech space (e.g., Acadia Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics) to determine if it aligns with industry norms for director compensation, considering the company's size, stage of development, and market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also potential benefit from aligned director incentives for long-term stock appreciation.
• Employees, Customers, Suppliers, Creditors: No direct or immediate impact is indicated by this routine compensation filing.

Next Steps

• The options will vest on the earlier of the first anniversary of the grant date (January 9, 2026) or the day immediately prior to the next annual meeting of stockholders.
• Michael Patrick Miller must continue in service as a non-employee director through the specified vesting date to receive the options.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a non-employee director as part of their compensation. Such grants are standard practice and do not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on their existing analysis of BioXcel Therapeutics' fundamentals and market position.

Keywords

BioXcel Therapeutics, BTAI, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Michael Patrick Miller